Department of Surgery, Sections of General Surgery (Horkoff) and Orthopaedic Surgery (Kendal), University of Calgary, Calgary, Alta.; Department of Surgery, Division of Pediatric General Surgery (Blackmore), Dalhousie University, Halifax, NS; Arnie Charbonneau Cancer Research Institute (Truong, Guilcher), Department of Oncology, and Alberta Children's Hospital Research Institute (Truong, Guilcher, Brindle), Department of Pediatrics, Cumming School of Medicine (Truong, Guilcher), and Department of Surgery (Brindle), Section of Pediatric Surgery, University of Calgary, Calgary, Alta.
Can J Surg. 2022 Aug 12;65(4):E527-E533. doi: 10.1503/cjs.008220. Print 2022 Jul-Aug.
Frequently occurring in adolescents, osteosarcoma is the most common primary malignant bone disease, with a reported 15% of patients who present with metastasis. With advances in imaging and improvements in surgical care, an updated analysis is warranted on the outcomes of pediatric patients with osteosarcoma.
We completed a retrospective review of pediatric patients who presented with osteosarcoma between 2001 and 2017, using The Cancer in Young People in Canada (CYP-C) national database. Data on 304 patients aged younger than 15 years were analyzed.
The proportion of patients who presented with metastasis was 23.0%. The overall 5-year survival (OS) for patients who presented with metastasis was 37.4%. Overall survival and event-free survival (EFS) were lower in these patients than in patients with localized disease (hazard ratio [HR] 4.3, < 0.0001 and HR 3.1, < 0.0001). For patients who presented with metastatic disease, the OS for those undergoing an operative intervention was 44.1% compared with 17.6% for those who did not undergo resection ( < 0.0001).
The proportion of patients who presented with metastatic osteosarcoma in our population is higher than previously reported. Overall outcomes of patients with metastatic disease have not changed. Our data reaffirm a role for surgical resection in patients with metastasis with a need to explore new treatment strategies to improve the overall prognosis of these patients.
骨肉瘤在青少年中经常发生,是最常见的原发性恶性骨病,据报道有 15%的患者就诊时已发生转移。随着影像学的进步和手术治疗的改善,有必要对患有骨肉瘤的儿科患者的结局进行更新分析。
我们使用加拿大年轻人癌症(CYP-C)国家数据库对 2001 年至 2017 年间就诊的患有骨肉瘤的儿科患者进行了回顾性研究。分析了 304 名年龄小于 15 岁的患者的数据。
有转移灶的患者比例为 23.0%。就诊时发生转移的患者的总体 5 年生存率(OS)为 37.4%。与局部疾病患者相比,这些患者的总生存(OS)和无事件生存(EFS)较低(风险比 [HR] 4.3,<0.0001 和 HR 3.1,<0.0001)。对于患有转移性疾病的患者,接受手术干预的患者的 OS 为 44.1%,而未行切除术的患者为 17.6%(<0.0001)。
我们人群中就诊时发生转移性骨肉瘤的患者比例高于先前报道。转移性疾病患者的总体结局没有改变。我们的数据再次证实了手术切除在转移性患者中的作用,需要探索新的治疗策略来改善这些患者的总体预后。